Daiichi Sankyo Company, Limited

TSE:4568 Stock Report

Market Cap: JP¥7.0t

Daiichi Sankyo Company Past Earnings Performance

Past criteria checks 4/6

Daiichi Sankyo Company has been growing earnings at an average annual rate of 26.2%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 15.3% per year. Daiichi Sankyo Company's return on equity is 18.2%, and it has net margins of 15.7%.

Key information

26.22%

Earnings growth rate

26.68%

EPS growth rate

Pharmaceuticals Industry Growth3.41%
Revenue growth rate15.29%
Return on equity18.22%
Net Margin15.68%
Last Earnings Update31 Mar 2025

Recent past performance updates

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Nov 07
Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Recent updates

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 30
Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?

Apr 06
Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

Feb 26
Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 04
Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

Daiichi Sankyo Company, Limited's (TSE:4568) Intrinsic Value Is Potentially 93% Above Its Share Price

Jan 14
Daiichi Sankyo Company, Limited's (TSE:4568) Intrinsic Value Is Potentially 93% Above Its Share Price

Daiichi Sankyo Company, Limited's (TSE:4568) Share Price Matching Investor Opinion

Nov 25
Daiichi Sankyo Company, Limited's (TSE:4568) Share Price Matching Investor Opinion

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Nov 07
Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors
author-image

Antibody-Drug Innovation And Strategic Partnerships Pave The Way For Significant Growth

Strategic R&D investments in antibody-drug conjugates and collaborations indicate potential future revenue growth and enhanced market share in oncology.

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 04
Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Sep 22
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Revenue & Expenses Breakdown

How Daiichi Sankyo Company makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4568 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 251,886,256295,756731,200435,965
31 Dec 241,795,986245,770722,045410,753
30 Sep 241,758,071250,400696,740392,404
30 Jun 241,687,028229,101675,532388,731
31 Mar 241,601,688200,731636,997365,169
31 Dec 231,503,471186,052578,348358,217
30 Sep 231,397,025147,885538,976357,008
30 Jun 231,348,996147,350511,428343,791
31 Mar 231,278,478109,188471,221341,570
31 Dec 221,182,20159,354435,551331,522
30 Sep 221,122,72462,816404,552301,836
30 Jun 221,061,14050,603375,565281,129
31 Mar 221,044,89266,972358,309260,228
31 Dec 211,034,69294,470357,377232,834
30 Sep 211,012,31386,756348,080231,885
30 Jun 21989,63879,321340,406232,560
31 Mar 21962,51675,958333,079227,353
31 Dec 20963,55270,599323,363224,168
30 Sep 20982,388116,315320,481216,129
30 Jun 20969,501117,584310,949205,104
31 Mar 20981,793129,074302,320197,465
31 Dec 19983,669148,891287,414198,066
30 Sep 19962,440113,821279,588195,904
30 Jun 19953,219112,805275,245199,435
31 Mar 19929,71793,409277,695203,711
31 Dec 18922,22866,479283,615203,000
30 Sep 18937,64870,018290,411206,117
30 Jun 18946,82955,081296,677233,531
31 Mar 18960,19560,282301,845236,046
31 Dec 17961,76637,887298,758246,479
30 Sep 17966,50938,758300,781242,153
30 Jun 17953,25552,017303,760215,721
31 Mar 17955,12453,466302,475214,347
31 Dec 16962,29659,736316,918214,027
30 Sep 16965,68160,572325,970216,074
30 Jun 16989,00177,951326,613211,564
31 Mar 16986,44682,282328,755208,656
31 Dec 15839,75955,256269,399186,615
30 Sep 15872,74467,132284,021190,206
30 Jun 15903,34061,708306,873191,180
31 Mar 15919,37246,762331,195190,666
31 Dec 141,149,34288,276266,861333,388
30 Sep 141,127,23380,437405,500185,139
30 Jun 141,120,17769,910361,139234,391

Quality Earnings: 4568 has a high level of non-cash earnings.

Growing Profit Margin: 4568's current net profit margins (15.7%) are higher than last year (12.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4568's earnings have grown significantly by 26.2% per year over the past 5 years.

Accelerating Growth: 4568's earnings growth over the past year (47.3%) exceeds its 5-year average (26.2% per year).

Earnings vs Industry: 4568 earnings growth over the past year (47.3%) exceeded the Pharmaceuticals industry 17.4%.

Return on Equity

High ROE: 4568's Return on Equity (18.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 02:16
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daiichi Sankyo Company, Limited is covered by 30 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
null nullBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research